Patents by Inventor Bruce Keyt

Bruce Keyt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
    Patent number: 9073998
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: July 7, 2015
    Assignee: Amgen Fremont Inc.
    Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
  • Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
    Patent number: 9062113
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: June 23, 2015
    Assignee: Amgen Fremont Inc.
    Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
  • ANTIBODIES IMMUNOREACTIVE WITH HEREGULIN-COUPLED HER3
    Publication number: 20140370548
    Abstract: Recombinant materials and methods for producing antibodies that specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer that expresses HER3.
    Type: Application
    Filed: September 2, 2014
    Publication date: December 18, 2014
    Inventors: Bruce KEYT, Lawrence M. KAUVAR, Ellen J. COLLARINI, Orit FOORD, Gizette SPERINDE, Marjan FATHOLAHI, Hung NGUYEN
  • Antibodies immunoreactive with heregulin-coupled HER3
    Patent number: 8828388
    Abstract: Antibodies which specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: September 9, 2014
    Assignee: Trellis Bioscience, LLC
    Inventors: Bruce Keyt, Lawrence M. Kauvar, Ellen J. Collarini, Orit Foord, Gizette Sperinde, Marjan Fatholahi, Hung Nguyen
  • ANTI-RSV G PROTEIN ANTIBODIES
    Publication number: 20130034564
    Abstract: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.
    Type: Application
    Filed: September 25, 2012
    Publication date: February 7, 2013
    Inventors: Lawrence M. KAUVAR, Ellen J. Collarini, Bruce Keyt, Orit Foord
  • Antibodies immunoreactive with heregulin-coupled HER3
    Patent number: 8362215
    Abstract: Antibodies which specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: January 29, 2013
    Assignee: Trellis Bioscience, LLC
    Inventors: Bruce Keyt, Lawrence M. Kauvar, Ellen J. Collarini, Orit Foord, Gizette Sperinde, Marjan Fatholahi, Hung Nguyen
  • Anti-RSV G protein antibodies
    Patent number: 8273354
    Abstract: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: September 25, 2012
    Assignee: Trellis RSV Holdings, Inc.
    Inventors: Lawrence M. Kauvar, Ellen J. Collarini, Bruce Keyt, Orit Foord
  • TREATMENT OF CANCER
    Publication number: 20120238601
    Abstract: The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.
    Type: Application
    Filed: December 12, 2011
    Publication date: September 20, 2012
    Applicant: BiPar Sciences, Inc.
    Inventors: Jerome MOORE, Bruce KEYT, John BURNIER, Barry SHERMAN, Max TOTROV, Valeria S. OSSOVSKAYA
  • Treatment of cancer
    Patent number: 8143447
    Abstract: The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.
    Type: Grant
    Filed: September 5, 2007
    Date of Patent: March 27, 2012
    Assignee: BiPar Sciences, Inc.
    Inventors: Jerome Moore, Bruce Keyt, John Burnier, Barry M. Sherman, Max Totrov, Valeria S. Ossovskaya
  • ANTIBODIES IMMUNOREACTIVE WITH HEREGULIN-COUPLED HER3
    Publication number: 20100310557
    Abstract: Antibodies which specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer.
    Type: Application
    Filed: April 29, 2010
    Publication date: December 9, 2010
    Inventors: Bruce KEYT, Lawrence M. KAUVAR, Ellen J. COLLARINI, Orit FOORD, Gizette SPERINDE, Marjan FATHOLAHI, Hung NGUYEN
  • ANTI-RSV G PROTEIN ANTIBODIES
    Publication number: 20100285022
    Abstract: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.
    Type: Application
    Filed: May 12, 2010
    Publication date: November 11, 2010
    Inventors: Lawrence M. KAUVAR, Ellen J. Collarini, Bruce Keyt, Orit Foord
  • Anti-RSV G protein antibodies
    Patent number: 7736648
    Abstract: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: June 15, 2010
    Assignee: Trellis Bioscience, Inc.
    Inventors: Lawrence M. Kauvar, Ellen J. Collarini, Bruce Keyt, Orit Foord
  • Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
    Patent number: 7736644
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: June 15, 2010
    Assignee: Amgen Fremont Inc.
    Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
  • ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF
    Publication number: 20100111979
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Application
    Filed: December 29, 2009
    Publication date: May 6, 2010
    Applicant: AMGEN FREMONT INC.
    Inventors: RICHARD WEBER, XIAO FENG, ORIT FOORD, LARRY GREEN, JEAN M. GUDAS, BRUCE KEYT, YING LIU, PALANISWAMI RATHANASWAMI, ROBERT RAYA, XIAO DONG YANG, JOSE CORVALAN, IAN FOLTZ, XIAO-CHI JIA, JASPAL S. KANG, CHADWICK T. KING, SCOTT L. KLAKAMP, QIAOJUAN JANE SU
  • Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
    Patent number: 7628986
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: December 8, 2009
    Assignee: Amgen Fremont Inc.
    Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
  • ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF
    Publication number: 20090240038
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Application
    Filed: March 2, 2009
    Publication date: September 24, 2009
    Applicant: Amgen Fremont Inc.
    Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
  • ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF
    Publication number: 20090175887
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Application
    Filed: March 2, 2009
    Publication date: July 9, 2009
    Applicant: Amgen Fremont Inc.
    Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
  • ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF
    Publication number: 20090155282
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Application
    Filed: November 10, 2008
    Publication date: June 18, 2009
    Applicant: Amgen Fremont Inc.
    Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
  • ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF
    Publication number: 20090156790
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Application
    Filed: November 10, 2008
    Publication date: June 18, 2009
    Applicant: Amgen Fremont Inc.
    Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
  • ANTI-RSV G PROTEIN ANTIBODIES
    Publication number: 20090130120
    Abstract: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.
    Type: Application
    Filed: October 24, 2008
    Publication date: May 21, 2009
    Inventors: Lawrence M. KAUVAR, Ellen J. Collarini, Bruce Keyt, Orit Foord